Target solid tumor T-cell therapy is expected to make new breakthrough

Photo Source: 123RFMultiantigen-specific T-Cell Therapy for Pancreatic Cancer Phase 1 Clinical Outcomesresearchers at Baylor College of Medicine published phase 1 clinical trial results for multi-antigen-specific T-cell therapy for pancreatic cancer patientsPancreatic cancer is a low proportion of cancer, but it is known as the "King of Cancer" because it is so deadlyAnd the standard treatment that most patients currently receive is chemotherapy, which has strong toxic side effects and patients are in dire need of other treatment optionsIn this study, scientists isolated T lymphocytes from the blood of pancreatic cancer patients targeting tumor-related antigens, namely PRAME, SSX2, MAGEA4, NY-ESO-1, and SurvivinThe researchers multiplied the cells in vitro and then re-delivered them back into the patientin Phase 1 clinical trials, a total of 18 pancreatic cancer patients were treated with this T-cell therapy, 9 of whom received first-line treatment in combination with T-cell therapy and chemotherapyOf the nine patients, five were in stable or remission, and one of them achieved full remissionThe duration of remission in patients reached 6-9 monthsOf the six patients who continued to develop the disease after chemotherapy, the treatment stabilized three of themNo patients developed systemic or neurotoxicity associated with T-cell therapy" pancreatic cancer is a very difficult cancer to treatMost patients receive severe side effects of vigorous chemotherapy, and we urgently need other treatments," said Study leader DrBrandon GSmaglo"We are pleased that this T-cell therapy for pancreatic cancer has shown good tolerance in clinical trials and shows signs of anti-cancer activity." We look forward to treating more patients and continue to observe the conditions of existing patients "
an individualized T-cell therapy initiates Phase 1 clinical trials one of the limitations of T-cell therapy mentioned above is the need to isolate and multiply T-cells in patients who target tumor-related antigens For some patients, the number of these T-cells may be too small to produce enough T-cells, or T-cell failure (T cell exhaustion) during proliferation, resulting in treatment that cannot be performed or reduced in efficacy PACT Pharma's individualized T-cell immunotherapy is committed to overcoming this deficiency The therapy first sequences the patient's tumor to find a genetic mutation that produces a new antigen( neoantigen) Based on this information, the company then uses the company's unique nanoparticle separation technology to isolate a small number of T-cells that have been targeted at these new antigens from the patient's T-cells The researchers then identified t-cell receptor (TCR) DNA sequences that encode targeting new antigens from these T-cells and imported them into the patient's own CD8-T cells through nonviral genomic engineering techniques the production process of personalized T-cell therapy for new antigens (Photo: PACTPharma's website) this production process does not require a substantial proliferation of T-cells, and can produce a large number of T-cells that target new antigens in the patient's tumor, which can quickly kill tumors that express the new antigen when it is returned to the patient." preclinical trial results presented at the AACR conference, researchers successfully identified T-cells targeting unique new antigens in tumors from a cancer patient who responded to PD-1 therapy Moreover, based on the TCR sequence information of these T-cells, the use of genetically engineered T-cell therapy can produce cancer-specific activity , the company has launched a Phase 1 clinical trial to test the safety and efficacy of this individualted T-cell therapy as a monotherapy, or in combination with PD-1 inhibitors, in patients with metastatic solid tumors compared to CAR-T cells, T-cell therapy that expresses TCR can target intracellular antigens, thus expanding the range of targets, while direct screening and proliferation of T-cells obtained in patients can avoid genetic engineering of T-cells and potential lying about genetic engineering We expect these different strategies for T-cell therapy to overcome the challenge synod synod and provide patients with innovative treatment options references: s1 s- s1 s-personalized gene-edited immune cell therapy for patients with solid cancers: New data si'r sialyse for verifying patient-specific cancer cancer s Retrieved July 22, 2019, from https:// 2 s Immune cell therapy show early make a makeover for patients with the trusc cancer Retrieved July 22, 2019, from https://medicalxpress.com/news/2019-07-immune-cell-therapy-early-patients.html 3, AACR Immune Cell Therapies: Early Study Suggest Activity of Multiantigen T-Cell Patients With WithCancer Cancer Retrieved July 22, 2019, from https://ascopost.com/News/60267 original title: Express - Target solid tumor, T-cell therapy is expected to make a breakthrough